Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Nicoletta Colombo, Emese Zsíros, Alexandra Sebastianelli, Radoslaw Madry, Carolina Ibañez, Jacob Korach, Kosei Hasegawa, Fatih Köse, Roberto Iván Romero Díaz, Emma Hudson, Jeffrey C. Goh, Ingrid Boere
+8 more Andreia Cristina de Melo, Hannelore Denys, Jae-Weon Kim, Thomas Jemielita, Karin Yamada, Agata M. Bogusz, Thibault De La Motte Rouge, Xiaohua Wu
DOI: 10.1016/j.ijgc.2025.102891
Cited by: 2

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
102891–102891
Publication date
1 February 2026
Language
EN